Differential effects of fingolimod on B-cell populations in multiple sclerosis.

@article{Nakamura2014DifferentialEO,
  title={Differential effects of fingolimod on B-cell populations in multiple sclerosis.},
  author={Masakazu Nakamura and Takako Matsuoka and Norio Chihara and Sachiko Miyake and Wakiro Sato and Manabu Araki and Tomoko Okamoto and Youwei Lin and Masafumi Ogawa and Miho Murata and Toshimasa Aranami and Takashi Yamamura},
  journal={Multiple sclerosis},
  year={2014},
  volume={20 10},
  pages={1371-80}
}
BACKGROUND Fingolimod is an oral drug approved for multiple sclerosis (MS) with an ability to trap central memory T cells in secondary lymphoid tissues; however, its variable effectiveness in individual patients indicates the need to evaluate its effects on other lymphoid cells. OBJECTIVE To clarify the effects of fingolimod on B-cell populations in patients with MS. METHODS We analysed blood samples from 9 fingolimod-treated and 19 control patients with MS by flow cytometry, to determine… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
16 Citations
35 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

Similar Papers

Loading similar papers…